ClinicalTrials.gg
CompletedNCT07478211MCM-LoopUpdated Sep 16, 2026

Menstrual Cycle Mapping While Using Closed-Loop Insulin Delivery

An observational study in Diabetes Mellitus, Type 1 and Energy Metabolism, sponsored by Lia Bally. Completed at 1 site in Switzerland. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-09-16.

Sponsored by Lia Bally · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
40
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 70 studies in Diabetes Mellitus, Type 1 with a site in Switzerland — 9 open to participants now, 10 under way, 4 of them phase 3. Diabetes Mellitus, Type 1 · Switzerland.

Enrollment
14th of 18
40 · median 73
Started
2025
with 3 others
Observational
18 of 70
4 open now
Registered
69th of 70
by date
Lead sponsor
3 of 70
Lia Bally

Among the 70 studies in Diabetes Mellitus, Type 1 with a site in Switzerland, this one is the 14th largest by enrollment of the 18 observational ones that give a count, is one of 4 that started in 2025, is one of 18 observational ones, and was the 69th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

9 of the 70 studies in Diabetes Mellitus, Type 1 with a site in Switzerland are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies in Diabetes Mellitus, Type 1 with a site in Switzerland, or all of them as a file.
02

Study summary

The hypothesis is that menstrual cyclicity affects glucose and energy metabolism in women with type 1 diabetes. The rationale of the hypothesis on cycle effects builds on the assumption that fluctuations of female sex hormones across the menstrual cycle cause changes in physiological parameters of glucose metabolism and energy homeostasis and/or lifestyle aspects involved in the regulation of blood glucose and body weight. It is expected that hormone fluctuations affect insulin sensitivity, gastric emptying, eating behaviour and energy expenditure. It is anticipated that insulin sensitivity is highest in the pre-ovulatory phase and lowest in the mid-luteal phase. It is further expected that gastric emptying peaks in the follicular phase, and highest energy expenditure and dietary intake are expected during the mid-luteal phase.

The primary objective of this study is to characterize glucose and energy metabolism throughout the menstrual cycle in natural cycling women with type 1 diabetes. Further objectives are to assess the impact of the menstrual cycle on glucose control and insulin requirements, investigate how fluctuations in sex hormone levels influence glucose and energy metabolism, and quantify both inter- and intra-individual variability in metabolic changes related to the menstrual cycle. Additionally, the study will evaluate whether changes in key physiological components of glucose metabolism and behavioural factors mediate menstrual cycle-related variations in glucose control and insulin requirements.

03

Conditions studied

  • Diabetes Mellitus, Type 1
  • Energy Metabolism

Keywords

  • Womens Health
  • Menstrual Cycle Physiology
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Eligible participants will be women aged 18-45 years, with a natural menstrual cycle (occurring without medical or hormonal interventions), who have Type 1 Diabetes and are willing to follow study-related procedures.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female sex assigned at birth
  • Type 1 diabetes for at least 12 months
  • Aged 18-45 years
  • Natural menstrual cycle (occurring without medical or hormonal interventions)
  • Functional insulin therapy delivered via injection or insulin pump
  • Willingness to follow study-related procedures
  • Willingness to use mechanical during the time of study participation

Exclusion criteria

Exclusion Criteria:

  • Use of or medical interventions that interfere with natural hormonal fluctuations of the menstrual cycle or cyclical bleeding
  • Interventions interfering with glucose or energy metabolism (other than insulin, thyroid hormone replacement or statins), as judged by the investigator, will be paused for the duration of the study, with an adequate duration prior to the start of data collection
  • Presence of any physical or psychological condition, or any medical intervention likely to interfere with the conduct of the procedures and/or their evaluation, as judged by the investigator
  • Pregnant or breast-feeding
  • Participation in another clinical study that interferes with the interpretation of the study results as judged by the investigator
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
40 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Women with Type 1 Diabetes

    Participants with type 1 diabetes from age 18 to 45 years and a natural menstrual cycle will be followed for 3 consecutive menstrual cycles.

06

What researchers measure

Primary outcomes

  1. Time in target glucose range

    The primary metric for glucose control is the proportion of time with sensor glucose levels in the target range (3.9-10mmol/L, %). Glucose levels will be measured using a continuous glucose monitoring sensor (Dexcom G6 or an equivalent CGM sensor).

    Time frame: Continuously over 3 menstrual cycles. Duration varies depending on individual cycle length, ranging from 60 days (20-day cycles) to 150 days (50-day cycles).

Secondary outcomes

  1. Algorithm-directed insulin delivery following a standardized meal

    The primary insulin metric is the algorithm-directed insulin dose (units) delivered over a 3 hour period following a standardized meal without a manual bolus. Insulin delivery is recorded using the mylife CamAPS FX automated insulin delivery system.

    Time frame: The outcome will be measured at each standardized meal assessment, performed during the three key menstrual cycle phases (early-follicular, pre-ovulatory, and mid-luteal),across three menstrual cycles, resulting in a total of nine 3-hour assessment times

  2. Insulin sensitivity

    Insulin sensitivity will be estimated continuously throughout the study from sensor glucose and insulin pump data, collected via the mylife CamAPS FX automated insulin delivery system, using mathematical modeling.

    Time frame: Continuously over three menstrual cycles. Duration varies depending on individual cycle length, ranging from 60 days (20-day cycles) to 150 days (50-day cycles).

  3. Gastric emptying

    This outcome is based in the \[13C\]-acetate breath test. Breath 13CO2 enrichment is analyzed using infrared spectrometry and kinetics parameters are derived using mathematical modelling. The main parameter of interest is T50 (ie., the time until half of the ingested meal was absorbed). This outcome is measured only in a subgroup of 15 participants.

    Time frame: The outcome is evaluated at each phase-specific assessment (early follicular, pre-ovulatory, and luteal) for one menstrual cycle.

  4. Total energy expenditure

    Total energy expenditure will be quantified using the doubly labelled water method. This outcome is measured only in a subgroup of 15 participants.

    Time frame: Continuously over one menstrual cycle. Duration varies depending on individual cycle length, ranging from 20 days to 50 days.

  5. Substrate oxidation

    Substrate oxidation (i.e, quantified by the relative contribution of fat oxidation to resting energy expenditure) will be measured by indirect calorimetry in the fasted state (≥8 hours) to provide additional context as a physiological determinant of glucose and energy metabolism. This outcome is measured only in a subgroup of 15 participants.

    Time frame: Assessed once at each phase-specific assessment (early follicular, pre-ovulatory, and luteal) for one menstrual cycle

  6. Dietary intake

    Total energy intake (kcal/day) will be assessed by recording all meals using an image-based automated food analysis application SNAQ.

    Time frame: Measured for 3 days following each phase-specific assessment (early follicular, pre-ovulatory, and luteal) across three menstrual cycles, totaling 27 days over 3 cycles

  7. Physical activity

    The number of steps per day, as a component of physical activity, will be measured using the Garmin Venu 3 smartwatch.

    Time frame: Continuously over 3 menstrual cycles. Duration varies depending on individual cycle length, ranging from 60 days (20-day cycles) to 150 days (50-day cycles).

Other outcomes

  1. Postprandial mean glucose

    Mean postprandial glucose levels measured using continuous glucose monitoring in the 3 hours following meals. Meal timepoints defined as manual carbohydrate entries in the mylife CamAPS FX automated insulin delivery system. This outcome serves as an additional metric within the overall assessment of glucose control. Additionally, mean postprandial glucose levels will be specifically measured in the 3 hours following the standardized meal assessment using continuous glucose monitoring.

    Time frame: The outcome will be evaluated continuously over 3 menstrual cycles (duration varies from 60 days (20-day cycles) to 150 days (50-day cycles)) as well as at each standardized meal assessment, resulting in a total of nine 3-hour assessment times.

  2. Postprandial peak glucose

    Peak postprandial glucose levels measured using continuous glucose monitoring in the 3 hours following meals. Meal timepoints defined as manual carbohydrate entries in the mylife CamAPS FX automated insulin delivery system. This outcome serves as an additional metric within the overall assessment of glucose control. Additionally, peak postprandial glucose levels will be specifically measuredin the 3 hours following the standardized meal assessment using continuous glucose monitoring.

    Time frame: The outcome will be evaluated continuously over 3 menstrual cycles (duration varies from 60 days (20-day cycles) to 150 days (50-day cycles)) as well as once for each standardized meal assessment (9 values in total).

  3. Proportion of time spent in the hyperglycaemic range

    Glucose levels above 10 mmol/L are classified as hyperglycaemic. Glucose levels will be measured using a continuous glucose monitoring (Dexcom G6 system or an equivalent CGM sensor). This outcome serves as an additional metric within the overall assessment of glucose control.

    Time frame: Continuously over 3 menstrual cycles. Duration varies depending on individual cycle length, ranging from 60 days (20-day cycles) to 150 days (50-day cycles)

  4. Proportion of time spent in hypoglycaemic range

    Glucose levels below 3.9 mmol/L are classified as hypoglycaemic. Glucose levels will be measured using continuous glucose monitoring (Dexcom G6 system or an equivalent CGM sensor) This outcome serves as an additional metric within the overall assessment of glucose control.

    Time frame: Continuously over 3 menstrual cycles. Duration varies depending on individual cycle length, ranging from 60 days (20-day cycles) to 150 days (50-day cycles).

  5. Glucose variability - standard deviation

    Glucose variability assessed as the standard deviation (SD) of sensor glucose values measured using continuous glucose monitoring. This outcome provides an additional metric contributing to the assessment of glucose variability and overall glucose control.

    Time frame: Continuously over 3 menstrual cycles. Duration varies depending on individual cycle length, ranging from 60 days (20-day cycles) to 150 days (50-day cycles).

  6. Glucose variability - coefficient of variation

    Glucose variability assessed as the coefficient of variation (CV) of sensor glucose values measured using continuous glucose monitoring data. This outcome provides an additional metric contributing to the assessment of glucose variability and overall glucose control.

    Time frame: Continuously over 3 menstrual cycles. Duration varies depending on individual cycle length, ranging from 60 days (20-day cycles) to 150 days (50-day cycles).

  7. Glucose variability - mean amplitude of glycaemic excursions

    Glucose variability assessed as the mean amplitude of glycaemic excursions (MAGE) derived from continuous glucose monitoring data. This outcome provides an additional metric contributing to the assessment of glucose variability and overall glucose control.

    Time frame: Continuously over 3 menstrual cycles. Duration varies depending on individual cycle length, ranging from 60 days (20-day cycles) to 150 days (50-day cycles).

  8. Total daily insulin dose

    Total daily insulin dose (U/day) will be evaluated using the mylife CamAPS FX automated insulin delivery system, which includes a continuous glucose monitoring sensor (Dexcom G6 or an equivalent CGM sensor for participants already using mylife CamAPS FX with a different sensor), an insulin pump (YpsoPump), and the CamAPS FX application. This outcome serves as an additional measure of individual insulin requirements.

    Time frame: Over 3 menstrual cycles. Duration varies depending on individual cycle length, ranging from 60 days (20-day cycles) to 150 days (50-day cycles).

  9. Basal insulin

    As an additional measure of insulin requirements, the proportion of basal insulin relative to total insulin delivery (%) will be assessed. It will be measured using the mylife CamAPS FX AID system consisting of a continuous glucose monitoring sensor (Dexcom G6 system or an equivalent CGM sensor if they already use the mylife CamAPS FX AID system with a different sensor), the insuline pump (Ypsopump) and the CamAPS FX app.

    Time frame: Continuously over 3 menstrual cycles. Duration varies depending on individual cycle length, ranging from 60 days (20-day cycles) to 150 days (50-day cycles).

  10. Bolus frequency

    Units are (n/day). The outcome is the number of manual boluses entered into the mylife CamAPS FX AID system.

    Time frame: Continuously over 3 menstrual cycles. Duration varies depending on individual cycle length, ranging from 60 days (20-day cycles) to 150 days (50-day cycles).

  11. Resting energy expenditure

    Resting energy expenditure (kcal/day) will be measured by indirect calorimetry in the fasted state (≥8 hours) to provide additional context as a physiological determinant of energy metabolism. This outcome is measured only in a subgroup of 15 participants.

    Time frame: Assessed once at each phase-specific assessment (early follicular, pre-ovulatory, and luteal) for one menstrual cycle.

  12. Model-estimated energy intake

    Daily energy intake (kcal/day) will be estimated using an energy balance model based on frequently measured body weight and physical activity data, and, where available, energy expenditure assessed using the doubly labeled water methodology. This outcome provides a complementary, model-based estimate of energy intake alongside self-reported dietary intake.

    Time frame: Continuously over three menstrual cycles. Duration varies depending on individual cycle length, ranging from 60 days (20-day cycles) to 150 days (50-day cycles).

  13. Proportion of carbohydrate intake

    The proportion of carbohydrate intake (% of total energy intake) will be derived from meal records collected using the image-based automated food analysis application (SNAQ), providing complementary information on macronutrient distribution.

    Time frame: Measured over 3 days following each phase-specific assessment (early follicular, pre-ovulatory, and luteal) across three menstrual cycles, totaling 27 days from 9 assessments.

  14. Proportion of fat intake

    The proportion of fat intake (% of total energy intake) will be derived from meal records collected using the image-based automated food analysis application (SNAQ), providing complementary information on macronutrient distribution.

    Time frame: Measured over 3 days following each phase-specific assessment (early follicular, pre-ovulatory, and luteal) across three menstrual cycles, totaling 27 days from 9 assessments.

  15. Proportion of protein intake

    The proportion of protein intake (% of total energy intake) will be derived from meal records collected using the image-based automated food analysis application (SNAQ), providing complementary information on macronutrient distribution.

    Time frame: Measured over 3 days following each phase-specific assessment (early follicular, pre-ovulatory, and luteal) across three menstrual cycles, totaling 27 days from 9 assessments.

  16. Dietary fiber intake

    Dietary fiber intake will be derived from meal records collected using the SNAQ application as an additional component of overall dietary intake assessment.

    Time frame: Total intake over 3 days following each phase-specific assessment (early follicular, pre-ovulatory, and luteal) across three menstrual cycles, totaling 27 days from 9 assessments.

  17. Food category distribution

    Food category distribution will be derived from meal records collected using the SNAQ application, providing complementary information on dietary patterns within overall dietary intake.

    Time frame: Measured continuously at every meal for 3 days following each phase-specific assessment (early follicular, pre-ovulatory, and luteal) across three menstrual cycles, totaling 27 days from 9 assessments.

  18. Activity minutes per day

    Active minutes per day will be measured using the Garmin Venu 3 smartwatch as a complementary indicator of physical activity.

    Time frame: Continuously over 3 menstrual cycles. Duration varies depending on individual cycle length, ranging from 60 days (20-day cycles) to 150 days (50-day cycles).

  19. Body weight

    Body weight will be measured using the Garmin Index S2 smart scale to provide additional metabolic context.

    Time frame: Measured daily over 3 menstrual cycles. Duration varies depending on individual cycle length, ranging from 60 days (20-day cycles) to 150 days (50-day cycles).

  20. Fat mass

    Percentage of body fat mass, as a component of body composition, will be measured using the Garmin Index S2 smart scale to provide additional metabolic context.

    Time frame: Daily over 3 menstrual cycles. Duration varies depending on individual cycle length, ranging from 60 days (20-day cycles) to 150 days (50-day cycles).

  21. Fat-free mass

    Percentage of fat-free mass, as a component of body composition, will be measured using the Garmin Index S2 smart scale to provide additional metabolic context.

    Time frame: Measured daily over three menstrual cycles. Duration varies depending on individual cycle length, ranging from 60 days (20-day cycles) to 150 days (50-day cycles).

  22. Beta-hydroxybutyrate levels

    Beta-hydroxybutyrate levels (mmol/L), will be assessed using the SiBio Ketone Sensor to provide additional metabolic context.

    Time frame: Continuously over 3 menstrual cycles. Duration varies depending on individual cycle length, ranging from 60 days (20-day cycles) to 150 days (50-day cycles).

  23. Heart rate

    Heart rate (bpm), will be assessed using the Garmin Venu 3 smartwatch to provide a broader metabolic context.

    Time frame: Continuously over 3 menstrual cycles. Duration varies depending on individual cycle length, ranging from 60 days (20-day cycles) to 150 days (50-day cycles).

  24. Heart rate variability

    Heart rate variability (High and low frequency components or equivalent time domain indices), will be assessed using the Garmin Venu 3 smartwatch to provide a broader metabolic context and as an indicator of autonomic nervous system activity.

    Time frame: Continuously over 3 menstrual cycles. Duration varies depending on individual cycle length, ranging from 60 days (20-day cycles) to 150 days (50-day cycles).

  25. Patient-reported perceived impact

    Perceived impact of the menstrual cycle on diabetes control and management will be captured retrospectively at the end of the study using an experience questionnaire.

    Time frame: At study completion (after three menstrual cycles).

  26. Patient-reported perceived impact - real-time electronic logs

    Perceived impact of the menstrual cycle on diabetes control and management will be captured additionally in real time using electronic logs in a smartphone app. Data are considered supplementary to the experience questionnaire-based assessment.

    Time frame: Continuously over three menstrual cycles. Duration varies depending on individual cycle length, ranging from 60 days (20-day cycles) to 150 days (50-day cycles).

07

Study locations

1 site
  • Department of Diabetes, Endocrinology, Nutritional Medicine and Metabolism (UDEM), Inselspital, Bern University Hospital
    Bern, Canton of Bern 3010, Switzerland
08

References and documents

Publications

  • Escalante Pulido JM, Alpizar Salazar M. Changes in insulin sensitivity, secretion and glucose effectiveness during menstrual cycle. Arch Med Res. 1999 Jan-Feb;30(1):19-22. doi: 10.1016/s0188-0128(98)00008-6. PubMed 10071420 ↗
  • Charkoudian N, Stachenfeld N. Sex hormone effects on autonomic mechanisms of thermoregulation in humans. Auton Neurosci. 2016 Apr;196:75-80. doi: 10.1016/j.autneu.2015.11.004. Epub 2015 Nov 30. PubMed 26674572 ↗
  • Hirshoren N, Tzoran I, Makrienko I, Edoute Y, Plawner MM, Itskovitz-Eldor J, Jacob G. Menstrual cycle effects on the neurohumoral and autonomic nervous systems regulating the cardiovascular system. J Clin Endocrinol Metab. 2002 Apr;87(4):1569-75. doi: 10.1210/jcem.87.4.8406. PubMed 11932284 ↗
  • Fede C, Albertin G, Petrelli L, Sfriso MM, Biz C, De Caro R, Stecco C. Hormone receptor expression in human fascial tissue. Eur J Histochem. 2016 Nov 2;60(4):2710. doi: 10.4081/ejh.2016.2710. PubMed 28076930 ↗
  • McEwen BS, Milner TA. Understanding the broad influence of sex hormones and sex differences in the brain. J Neurosci Res. 2017 Jan 2;95(1-2):24-39. doi: 10.1002/jnr.23809. PubMed 27870427 ↗
  • Mayes JS, Watson GH. Direct effects of sex steroid hormones on adipose tissues and obesity. Obes Rev. 2004 Nov;5(4):197-216. doi: 10.1111/j.1467-789X.2004.00152.x. PubMed 15458395 ↗
  • Sherman BM, Korenman SG. Hormonal characteristics of the human menstrual cycle throughout reproductive life. J Clin Invest. 1975 Apr;55(4):699-706. doi: 10.1172/JCI107979. PubMed 1120778 ↗

Individual participant data

Plan to share: Yes — Individual participant data (IPD) will be made available upon reasonable request to the principal investigator.

Supporting information: Study protocol, Analytic code

Time frame: IPD will be made availabe starting 12 month after publication of trial results.

Access criteria: Ethics approval, as applicable under Swiss legislation, will need to be obtained by those requesting the data. Additionally, a data transfer and processing agreement must be in place to ensure compliance with data protection regulations.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2025 to primary completion in Sep 2026, 15 months.

Of 248 non-industry observational studies under Diabetes Mellitus, Type 1, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 78. This study's 15 months is below that.

Counting every sponsor, half of 298 studies reached it within 28 months; a quarter within 12 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2025
First posted
Mar 17, 2026
StartActual
May 9, 2025
Primary completionActual
Sep 8, 2026
CompletionActual
Sep 8, 2026
Last update
Sep 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07478211
Lead sponsor
Lia Bally
Collaborators
Gertrud and Walter Siegenthaler Foundation, Bangerter Foundation and Swiss Academy of Medical Science, Innosuisse - Swiss Innovation Agency, CSEM Centre Suisse d'Electronique et de Microtechnique SA - Recherche et Developpement, University of Bern, Insel Gruppe AG, University Hospital Bern, DexCom, Inc., Fresenius Kabi (Schweiz) AG, Bern Medtech Collaboration Call, mylife Diabetescare AG, Burgergemeinde Bern
Responsible party
Lia Bally (Prof. Dr. med. et phil., Insel Gruppe AG, University Hospital Bern) — Sponsor-investigator
First posted
Mar 17, 2026
Start date
May 9, 2025
Primary completion
Sep 8, 2026
Completion
Sep 8, 2026
Last update
Sep 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion